PerpEquities

Equity · Healthcare

Guardant Health, Inc. (GH) perpetual futures

Guardant Health is a precision oncology company providing liquid biopsy blood tests, clinical-genomic datasets, and analytical solutions for cancer patients and biopharmaceutical clients.

$145.90Market closed until the venue's next session · last quote Nov 20, 20:59 UTCNASDAQ closed
Open in terminal

Price chart

Interactive TradingView chart

TradingView symbol NASDAQ:GH

Loads TradingView's third-party widget (about 1 MB) on demand.

Auto: underlying reference priceOpen in TradingView

Trading data

Perpetual market activity

0/1 live markets
Venues
0
Live markets
0/1
24h volume
-
Open interest
-
Best liquidity
-
Tightest spread
-
Highest volume
-
Settlement mix
USDT · 1/1
Perp/spot vol.
-
Spot performance
1D+0.16%
5D-2.49%
1M-12.50%
6M+23.57%
YTD+42.77%
1Y+38.33%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BingXTradeGH-USDTWatchlist------USDT-
Best venues for this underlying

Best liquidity

-
No live data-

Tightest spread

-
No live data-

Highest volume

-
No live data-

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-11-05 · next report 2027-02-18 · Updated 2h ago
All financials →

Valuation & key figures

Market cap
$19.7B
Updated 2h ago
Revenue
$1.28B
Trailing 12 months
Revenue growth
+39%
FY2026 consensus
Profit margin
-37.9%
Net income / revenue, TTM
P/E
No P/E
Loss in the last twelve months
P/S
15.4×
Price / sales, TTM
Peer P/E
30.6×
Similar listed perps
EV / EBITDA
-46.2×
TTM
Free cash flow
-$232M
Trailing 12 months
Net income
-$485M
Trailing 12 months
Revenue estimate
$1.37B
FY2026 consensus
Earnings
2027-02-18
Revenue est. $371M · Updated 2h ago
Dividend
–
No dividend
Revenue (TTM)$1.28B+41.7% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)-39.4%+9.6 pp vs a year agoOperating income -$504M
Net income (TTM)-$485M-21.6% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)-$232M+11.5% vs a year agoCapex $58.7M
Diluted EPS (TTM)-$3.68-14.6% vs a year agoSum of the last 4 quarters
Net cash-$665M+11.0% vs a year agoCash + short-term investments - debt
  • Last report (2026-11-05): revenue beat by 2.9%, EPS beat by 61.3%Revenue $361M vs $351M expected (+2.9%); EPS -$0.29 vs -$0.75 (+61.3%).
  • Revenue growth slowing: 36.1% year on yearQ3 '26 revenue $361M, against an average of 42.6% over the four quarters before.
  • Operating margin -39.4% (TTM), +9.6 pp on a year agoOperating income grew -13.9% while revenue grew 41.7%.
  • Capex 4.6% of revenue (a year ago 4.4%)$58.7M invested in the last 4 quarters (+49.2% on a year earlier). Free cash flow -$232M.

Revenue, operating income and growth

quarterly

Revenue by business line

Q3 '26
LineRevenuey/yShare of listed
Oncology$231M+25.4%64.1%
Screening$67.6M+180.4%18.7%
Biopharma & Data$59M+7.7%16.3%
Licensing & Other$3.13M+60.2%0.9%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 245 lines Guardant Health, Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-18
Revenue est. $371M · Updated 2h ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-3.44$1.4B+39%13
FY 2027-2.27$1.8B+34%13
FY 2028-0.44$2.5B+37%11
FY 20290.62$3.2B+28%4
FY 20300.69$3.8B+20%4
Q1 2027-0.73$394.3M+31%7
Source: FMP · Consensus

Company events

6
2027-02-18EarningsActual - / Estimate -0.748-
2026-11-05EarningsActual -0.29 / Estimate -0.75Beat
2026-07-30EarningsActual -0.9 / Estimate -0.762Miss
2026-05-07EarningsActual -0.85 / Estimate -0.806Miss
2026-02-19EarningsActual -1.00 / Estimate -0.767Miss
2025-10-29EarningsActual -0.74 / Estimate -0.79Beat

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 22, 2026, 01:23 AM UTC

Company profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Chief executive
Helmy Eltoukhy
Employees
2,498
IPO date
Oct 4, 2018
Country
US
Exchange
NASDAQ Global Select
Website
Altman Z-scorei3.66
Piotroski scorei3/9
Overall ratingiC
Owner earningsi$8.33M$0.06 per share
ESG risk ratingiB-Industry rank: 43/62

Rating factors

Return on equityi
5/5
Return on assetsi
1/5
Debt to equityi
1/5
Price to earningsi
1/5
Price to booki
1/5
Market cap history
$19.60B-13.0%Aug 2026 – Nov 2026
$19.36B$22.04B$24.73BHigh: $24.73B · 2026-10-05Low: $19.36B · 2026-11-16Latest: $19.60B · 2026-11-20Aug 2026Sep 2026Oct 2026Nov 2026
Latest: $19.60B · 2026-11-20High: $24.73B · 2026-10-05Low: $19.36B · 2026-11-16
Largest fund holders
FundWeightShares held
ANNPX1.21%10.6M
VTI0.03%3.2M
NJM0.47%2.9M
VB0.28%2.9M
NCV0.76%2.6M
NFJ0.31%2M
NIE0.45%2M
NCZ0.77%2M
VBK0.66%1.6M
VXF0.29%1.5M
ACV0.69%1.5M
NLO0.89%1M

Analyst track record

How the analysts covering GH have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings169409
Analysts3141
Buy / hold / sell165 / 4 / 0404 / 5 / 0
Upgrades / downgrades / initiations1 / 1 / 63 / 1 / 13
Price targets hit / missed79 / 73 (52%)280 / 73 (79%)
Avg. return after a rating (TipRanks)+0.2%+117.4%
Best / worst call+78.5% / -32.6%+911.3% / -32.6%

After buy calls on this stock: median 21-day move +3.3% vs S&P 500 +3.4% (n = 404)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Daniel BrennanTD Cowen100% hit rate on this stock · 14 targets measuredBuytarget $220Nov 6, 2026
  2. Michael RyskinBank of America Securities100% hit rate on this stock · 12 targets measuredBuytarget $200Oct 9, 2026
  3. Luke SergottBarclays100% hit rate on this stock · 11 targets measuredBuytarget $220Nov 6, 2026

Latest ratings

DateAnalystCallTarget
Nov 18, 2026Eve BursteinBernsteinNov 18, 2026BuyMaintained$190↗
Nov 10, 2026David WestenbergPiper SandlerNov 10, 2026BuyReiterated$190↗
Nov 6, 2026Lu LiBank of America SecuritiesNov 6, 2026BuyMaintained–↗
Nov 6, 2026Daniel AriasStifel NicolausNov 6, 2026BuyMaintained$180↗
Nov 6, 2026Evie KosloskyGoldman SachsNov 6, 2026BuyMaintained$210↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$80.00$100$120$140$160$180$200Dec 25 · Buy 24 · Hold 0 · Sell 0Dec 25Jan 26 · Buy 23 · Hold 1 · Sell 0Feb 26 · Buy 24 · Hold 1 · Sell 0Feb 26Mar 26 · Buy 21 · Hold 1 · Sell 0Apr 26 · Buy 20 · Hold 1 · Sell 0Apr 26May 26 · Buy 20 · Hold 1 · Sell 0Jun 26 · Buy 23 · Hold 0 · Sell 0Jun 26Jul 26 · Buy 24 · Hold 0 · Sell 0Aug 26 · Buy 23 · Hold 0 · Sell 0Aug 26Sep 26 · Buy 27 · Hold 0 · Sell 0Oct 26 · Buy 29 · Hold 0 · Sell 0Oct 26Nov 26 · Buy 29 · Hold 0 · Sell 0Dec 25 · avg. target $106Jan 26 · avg. target $114Feb 26 · avg. target $122Mar 26 · avg. target $130Apr 26 · avg. target $128May 26 · avg. target $133Jun 26 · avg. target $146Jul 26 · avg. target $176Aug 26 · avg. target $188Sep 26 · avg. target $193Oct 26 · avg. target $197Nov 26 · avg. target $198Dec 25 · month-end close $102Jan 26 · month-end close $114Feb 26 · month-end close $93.90Mar 26 · month-end close $92.37Apr 26 · month-end close $87.08May 26 · month-end close $130Jun 26 · month-end close $150Jul 26 · month-end close $162Aug 26 · month-end close $159Sep 26 · month-end close $178Oct 26 · month-end close $179Nov 26 · month-end close $146

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 19, 2026 · 169 ratings

Embed this asset

GH perpetuals · perpequities.comGH perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/gh-perp"><img src="https://perpequities.com/badge/gh-perp.svg" width="240" height="64" alt="GH perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of GH perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for GH — one email every Sunday.

Watchlist and alerts

Price and funding alerts for GH, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X